Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
This list of potential positions covers Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery in USA. Please note, we provide buy hold or sell recommendation only in the context of selected investment horizon assuming investor has average attitude towards taking risk. Please also consider using Portfolio Positions Ratings and Equity Ratings tools to further calibrate your research.
Story appears to be empty
Align Technology (ALGN)
The company has return on total asset (ROA) of 0.0682 % which means that it generated a profit of $0.0682 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1231 %, meaning that it created $0.1231 on every $100 dollars invested by stockholders. Align Technology's management efficiency ratios could be used to measure how well Align Technology manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Align Technology's Return On Tangible Assets are very stable compared to the past year. As of the 16th of April 2024, Return On Capital Employed is likely to grow to 0.17, while Return On Equity is likely to drop 0.09. At this time, Align Technology's Intangible Assets are very stable compared to the past year. As of the 16th of April 2024, Net Tangible Assets is likely to grow to about 3.7 B, while Deferred Long Term Asset Charges is likely to drop about 52.9 M. The entity currently falls under 'Large-Cap' category with a current market capitalization of 22.93 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Align Technology's market, we take the total number of its shares issued and multiply it by Align Technology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be overvalued. Align Technology shows a prevailing Real Value of $281.47 per share. The current price of the firm is $304.74. Our model approximates the value of Align Technology from analyzing the firm fundamentals such as Return On Equity of 0.12, profit margin of 0.12 %, and Current Valuation of 22.04 B as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor obtaining undervalued instruments and abandoning overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Varian Medical Systems (VAR)
The company has Return on Asset of 5.92 % which means that on every $100 spent on assets, it made $5.92 of profit. This is considered to be average in the sector. In the same way, it shows a return on shareholders' equity (ROE) of 13.51 %, implying that it generated $13.51 on every 100 dollars invested. Varian Medical's management efficiency ratios could be used to measure how well Varian Medical manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Large-Cap' category with a total capitalization of 16.27 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Varian Medical's market, we take the total number of its shares issued and multiply it by Varian Medical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Biogen Inc (BIIB)
The company has return on total asset (ROA) of 0.0458 % which means that it generated a profit of $0.0458 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0824 %, meaning that it created $0.0824 on every $100 dollars invested by stockholders. Biogen's management efficiency ratios could be used to measure how well Biogen manages its routine affairs as well as how well it operates its assets and liabilities. At present, Biogen's Return On Capital Employed is projected to increase slightly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.06, whereas Return On Tangible Assets are forecasted to decline to 0.08. At present, Biogen's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 21 B, whereas Non Currrent Assets Other are forecasted to decline to about 270.1 M. This firm currently falls under 'Large-Cap' category with a current market capitalization of 28.81 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Biogen's market, we take the total number of its shares issued and multiply it by Biogen's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be undervalued. Biogen Inc shows a prevailing Real Value of $233.68 per share. The current price of the firm is $196.8. Our model approximates the value of Biogen Inc from analyzing the firm fundamentals such as Current Valuation of 34.99 B, profit margin of 0.12 %, and Return On Equity of 0.0824 as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor taking in undervalued instruments and trading overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Teva Pharma Industries (TEVA)
The company has return on total asset (ROA) of 0.0454 % which means that it generated a profit of $0.0454 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0736) %, meaning that it created substantial loss on money invested by shareholders. Teva Pharma's management efficiency ratios could be used to measure how well Teva Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.03. In addition to that, Return On Capital Employed is expected to decline to 0.01. At present, Teva Pharma's Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 914.4 M, whereas Total Assets are forecasted to decline to about 26.4 B. The company currently falls under 'Large-Cap' category with a current market capitalization of 15.63 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Teva Pharma's market, we take the total number of its shares issued and multiply it by Teva Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Short Long Term Debt Total
21.16 Billion
At present, Teva Pharma's Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting.
Bristol Myers Squibb (BMY)
The company has Return on Asset of 0.0563 % which means that on every $100 spent on assets, it made $0.0563 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2653 %, implying that it generated $0.2653 on every 100 dollars invested. Bristol Myers' management efficiency ratios could be used to measure how well Bristol Myers manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Bristol Myers' Return On Capital Employed is fairly stable compared to the past year. Return On Assets is likely to rise to 0.14 in 2024, whereas Return On Tangible Assets are likely to drop 0.15 in 2024. At this time, Bristol Myers' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 66.6 B in 2024, whereas Other Assets are likely to drop slightly above 3.3 B in 2024. The entity currently falls under 'Large-Cap' category with a total capitalization of 98.32 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bristol Myers's market, we take the total number of its shares issued and multiply it by Bristol Myers's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be undervalued. Bristol Myers Squibb shows a prevailing Real Value of $60.51 per share. The current price of the firm is $48.28. Our model approximates the value of Bristol Myers Squibb from analyzing the firm fundamentals such as Current Valuation of 126.93 B, profit margin of 0.18 %, and Return On Equity of 0.27 as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor acquiring undervalued instruments and dropping overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Macroaxis financial leverage refers to using borrowed capital as a funding source to finance Macroaxis ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Macroaxis financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Macroaxis' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Macroaxis' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Macroaxis's total debt and its cash.
Macroaxis Gross Profit
Macroaxis Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Macroaxis previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Macroaxis Gross Profit growth over the last 10 years. Please check Macroaxis' gross profit and other fundamental indicators for more details.
Story appears to be empty
Align Technology (ALGN)
The company has return on total asset (ROA) of 0.0682 % which means that it generated a profit of $0.0682 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1231 %, meaning that it created $0.1231 on every $100 dollars invested by stockholders. Align Technology's management efficiency ratios could be used to measure how well Align Technology manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Align Technology's Return On Tangible Assets are very stable compared to the past year. As of the 16th of April 2024, Return On Capital Employed is likely to grow to 0.17, while Return On Equity is likely to drop 0.09. At this time, Align Technology's Intangible Assets are very stable compared to the past year. As of the 16th of April 2024, Net Tangible Assets is likely to grow to about 3.7 B, while Deferred Long Term Asset Charges is likely to drop about 52.9 M. The entity currently falls under 'Large-Cap' category with a current market capitalization of 22.93 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Align Technology's market, we take the total number of its shares issued and multiply it by Align Technology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be overvalued. Align Technology shows a prevailing Real Value of $281.47 per share. The current price of the firm is $304.74. Our model approximates the value of Align Technology from analyzing the firm fundamentals such as Return On Equity of 0.12, profit margin of 0.12 %, and Current Valuation of 22.04 B as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor obtaining undervalued instruments and abandoning overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Varian Medical Systems (VAR)
The company has Return on Asset of 5.92 % which means that on every $100 spent on assets, it made $5.92 of profit. This is considered to be average in the sector. In the same way, it shows a return on shareholders' equity (ROE) of 13.51 %, implying that it generated $13.51 on every 100 dollars invested. Varian Medical's management efficiency ratios could be used to measure how well Varian Medical manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Large-Cap' category with a total capitalization of 16.27 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Varian Medical's market, we take the total number of its shares issued and multiply it by Varian Medical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Biogen Inc (BIIB)
The company has return on total asset (ROA) of 0.0458 % which means that it generated a profit of $0.0458 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0824 %, meaning that it created $0.0824 on every $100 dollars invested by stockholders. Biogen's management efficiency ratios could be used to measure how well Biogen manages its routine affairs as well as how well it operates its assets and liabilities. At present, Biogen's Return On Capital Employed is projected to increase slightly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.06, whereas Return On Tangible Assets are forecasted to decline to 0.08. At present, Biogen's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 21 B, whereas Non Currrent Assets Other are forecasted to decline to about 270.1 M. This firm currently falls under 'Large-Cap' category with a current market capitalization of 28.81 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Biogen's market, we take the total number of its shares issued and multiply it by Biogen's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be undervalued. Biogen Inc shows a prevailing Real Value of $233.68 per share. The current price of the firm is $196.8. Our model approximates the value of Biogen Inc from analyzing the firm fundamentals such as Current Valuation of 34.99 B, profit margin of 0.12 %, and Return On Equity of 0.0824 as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor taking in undervalued instruments and trading overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Teva Pharma Industries (TEVA)
The company has return on total asset (ROA) of 0.0454 % which means that it generated a profit of $0.0454 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0736) %, meaning that it created substantial loss on money invested by shareholders. Teva Pharma's management efficiency ratios could be used to measure how well Teva Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.03. In addition to that, Return On Capital Employed is expected to decline to 0.01. At present, Teva Pharma's Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 914.4 M, whereas Total Assets are forecasted to decline to about 26.4 B. The company currently falls under 'Large-Cap' category with a current market capitalization of 15.63 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Teva Pharma's market, we take the total number of its shares issued and multiply it by Teva Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Short Long Term Debt Total
21.16 Billion
At present, Teva Pharma's Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting.
Bristol Myers Squibb (BMY)
The company has Return on Asset of 0.0563 % which means that on every $100 spent on assets, it made $0.0563 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2653 %, implying that it generated $0.2653 on every 100 dollars invested. Bristol Myers' management efficiency ratios could be used to measure how well Bristol Myers manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Bristol Myers' Return On Capital Employed is fairly stable compared to the past year. Return On Assets is likely to rise to 0.14 in 2024, whereas Return On Tangible Assets are likely to drop 0.15 in 2024. At this time, Bristol Myers' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 66.6 B in 2024, whereas Other Assets are likely to drop slightly above 3.3 B in 2024. The entity currently falls under 'Large-Cap' category with a total capitalization of 98.32 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bristol Myers's market, we take the total number of its shares issued and multiply it by Bristol Myers's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be undervalued. Bristol Myers Squibb shows a prevailing Real Value of $60.51 per share. The current price of the firm is $48.28. Our model approximates the value of Bristol Myers Squibb from analyzing the firm fundamentals such as Current Valuation of 126.93 B, profit margin of 0.18 %, and Return On Equity of 0.27 as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor acquiring undervalued instruments and dropping overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Please refer to our Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com
Did you try this?
Run Fundamentals Comparison Now
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any private could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
